Chenodeoxycholic Acid Leadiant

What Is Chenodeoxycholic Acid Leadiant and What Is It Used For?

Chenodeoxycholic acid Leadiant is an orphan medicine containing the naturally occurring primary bile acid chenodeoxycholic acid (CDCA). It is specifically indicated for the treatment of cerebrotendinous xanthomatosis (CTX), a rare inherited metabolic disorder caused by mutations in the CYP27A1 gene, which encodes the enzyme sterol 27-hydroxylase.

Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disease in which the body cannot properly convert cholesterol into bile acids. The enzyme sterol 27-hydroxylase, essential for the final steps of bile acid synthesis, is deficient or absent. This leads to a dramatically reduced production of chenodeoxycholic acid and cholic acid, while toxic metabolic by-products — particularly cholestanol and bile alcohols — accumulate in various tissues throughout the body.

The accumulation of cholestanol is especially damaging. It deposits in the brain, tendons, eyes, and blood vessels, causing a progressive and often devastating multi-system disease. Without treatment, patients typically develop childhood-onset chronic diarrhoea, juvenile cataracts, tendon xanthomas (lipid deposits in tendons, particularly the Achilles tendon), and progressive neurological deterioration including cerebellar ataxia, spasticity, cognitive decline, and psychiatric symptoms.

Chenodeoxycholic acid Leadiant works by replacing the missing primary bile acid. When administered orally, CDCA is absorbed in the small intestine and enters the enterohepatic circulation. It exerts negative feedback on the hepatic enzyme cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting step in bile acid synthesis. This suppresses the alternative metabolic pathways that produce excessive cholestanol and toxic bile alcohols, thereby normalising their plasma and tissue levels.

The European Medicines Agency (EMA) granted marketing authorisation for Chenodeoxycholic acid Leadiant in 2017 under the orphan designation, recognising the critical unmet medical need for CTX patients. Clinical evidence, although largely based on case series and observational studies due to the rarity of the condition, consistently demonstrates that CDCA therapy effectively reduces serum cholestanol levels, stabilises or improves neurological function, prevents cataract formation, and halts the progression of tendon xanthomas when started early.

How common is CTX?

CTX is classified as an ultra-rare disease with an estimated prevalence of approximately 1 in 50,000 to 1 in 70,000 people globally, though experts believe the condition is significantly underdiagnosed. The disease has been reported worldwide across all ethnic groups, with higher prevalence noted in certain populations with higher rates of consanguinity. As of recent estimates, only a few hundred patients have been diagnosed worldwide, though the true number is likely considerably higher.

When should treatment be started?

Treatment with chenodeoxycholic acid should be initiated as soon as CTX is diagnosed, regardless of the patient's age or symptom severity. The evidence strongly supports early treatment: patients who begin CDCA therapy before the onset of significant neurological symptoms have markedly better long-term outcomes. In children diagnosed through family screening or early symptom recognition, treatment can prevent the development of cataracts, xanthomas, and neurological damage entirely. Even in patients with established neurological disease, CDCA therapy can stabilise symptoms and slow or halt further progression.

What Should You Know Before Taking Chenodeoxycholic Acid Leadiant?

Before starting Chenodeoxycholic acid Leadiant, your physician must confirm the diagnosis of CTX through genetic testing or biochemical analysis. The medicine is contraindicated in patients with known hypersensitivity to chenodeoxycholic acid and is not recommended during pregnancy or breastfeeding.

Contraindications

Chenodeoxycholic acid Leadiant must not be used in the following situations:

• Hypersensitivity to chenodeoxycholic acid or any of the excipients listed in the product composition
• Pregnancy — animal studies have shown teratogenic and foetotoxic effects. Women of childbearing potential must use effective contraception during treatment

It is important to note that unlike the historical use of chenodeoxycholic acid for gallstone dissolution (which was contraindicated in patients with gallbladder disease, hepatic impairment, and inflammatory bowel disease), the use of CDCA in CTX is a fundamentally different clinical context. In CTX patients, CDCA replaces a deficient endogenous bile acid rather than providing a pharmacological excess. However, your physician will still carefully evaluate your liver function before and during treatment.

Warnings and Precautions

Several important precautions apply to the use of Chenodeoxycholic acid Leadiant:

• Liver function monitoring: Regular liver function tests (LFTs) are required, particularly during the first months of treatment and after dose adjustments. Transient elevations in liver transaminases have been reported. If significant hepatic abnormalities occur, dose reduction or temporary discontinuation may be necessary
• Dose-related diarrhoea: Diarrhoea is the most common side effect and is typically dose-related. If persistent diarrhoea occurs, the dose should be reduced and then gradually increased as tolerated
• Cholestanol monitoring: Serum cholestanol levels should be monitored regularly to ensure adequate suppression and to guide dose adjustments. The target is normalisation of cholestanol to within the reference range
• Specialist supervision: Treatment should only be initiated and monitored by a physician experienced in the management of CTX or inborn errors of bile acid metabolism

Pregnancy and Breastfeeding

Chenodeoxycholic acid Leadiant is not recommended during pregnancy. Preclinical studies in animals have demonstrated teratogenic effects, including skeletal abnormalities and visceral malformations. There are no adequate or well-controlled studies in pregnant women. Women of childbearing potential must use effective contraception throughout the duration of treatment. If a patient becomes pregnant or plans to become pregnant, the treating physician must be consulted immediately to reassess the benefit-risk balance.

It is not known whether chenodeoxycholic acid is excreted in human breast milk. Given that bile acids are naturally present in breast milk and that the potential risk to the nursing infant cannot be excluded, a decision must be made whether to discontinue breastfeeding or to continue treatment, taking into account the critical importance of the therapy for the mother. In most cases, given that CTX treatment is lifelong and essential, discussion with a specialist is crucial.

Use in Children

Chenodeoxycholic acid Leadiant can be used in paediatric patients. Indeed, early treatment in children is strongly recommended as it offers the best opportunity to prevent irreversible organ damage. The dose for children is adjusted based on body weight, typically starting at 5 mg/kg/day and adjusted according to cholestanol levels and tolerability. For young children who cannot swallow capsules, the capsules may be opened and the contents mixed with a small amount of sodium bicarbonate solution, as directed by the prescribing physician.

How Does Chenodeoxycholic Acid Leadiant Interact with Other Drugs?

Chenodeoxycholic acid Leadiant can interact with bile acid sequestrants (cholestyramine, colestipol), aluminium-based antacids, certain lipid-lowering agents, and immunosuppressants such as ciclosporin. These interactions may reduce the absorption or effectiveness of CDCA or alter the effects of co-administered medicines.

Drug interactions involving chenodeoxycholic acid are primarily related to its physicochemical properties as a bile acid and its effects on bile acid metabolism. Understanding these interactions is essential for safe and effective treatment of CTX.

Major Interactions

The most clinically significant interactions involve bile acid sequestrants such as cholestyramine and colestipol. These medications are designed to bind bile acids in the intestinal lumen, which directly opposes the therapeutic mechanism of Chenodeoxycholic acid Leadiant. Co-administration would prevent adequate CDCA absorption and could lead to treatment failure with rising cholestanol levels and disease progression. If bile acid sequestrants are medically necessary for another indication, strict separation of dosing times (minimum 5 hours) and close monitoring of serum cholestanol levels are essential.

Minor Interactions

Oestrogen-containing oral contraceptives and certain hepatic enzyme inducers such as phenobarbital may have minor effects on CDCA metabolism or effectiveness. These interactions are generally manageable with appropriate monitoring. Patients should inform their physician about all medications, including over-the-counter medicines and herbal supplements, particularly those affecting liver function or gastrointestinal absorption. St John's wort, for example, is a potent enzyme inducer that could theoretically affect bile acid metabolism and should be discussed with the treating physician.

What Is the Correct Dosage of Chenodeoxycholic Acid Leadiant?

The dose of Chenodeoxycholic acid Leadiant is individually adjusted based on body weight, serum cholestanol levels, and liver function. Adults typically take 750 mg per day (three 250 mg capsules), divided into three doses. Children receive a weight-based dose starting at approximately 5 mg/kg/day. Capsules should be swallowed whole with water.

Dosing of Chenodeoxycholic acid Leadiant requires careful individualisation by a specialist physician experienced in treating CTX. The goal of treatment is to normalise serum cholestanol levels while minimising side effects, particularly diarrhoea. Treatment is lifelong, and dose adjustments may be needed over time based on biochemical monitoring and clinical response.

Adults

The recommended starting dose for adults is 750 mg per day, which corresponds to three 250 mg capsules divided into three separate doses taken throughout the day (one capsule with each main meal, or as directed by the physician). The capsules should be swallowed whole with a glass of water and can be taken with or without food, although taking them with meals may improve tolerability and absorption.

The dose may be adjusted by the physician based on serum cholestanol monitoring. Some patients may require up to 1000 mg per day (four capsules) to achieve adequate cholestanol suppression, while others may be adequately treated with 500 mg per day (two capsules). The lowest effective dose that maintains cholestanol within the reference range should be used to minimise the risk of dose-related side effects.

Children

In paediatric patients, the dose is calculated based on body weight, typically starting at 5 mg/kg/day. The total daily dose is divided into three administrations. For infants and young children who cannot swallow capsules, the capsule contents may be emptied and mixed with a small volume of 8.4% sodium bicarbonate solution to form a suspension, which is then administered orally via a syringe or spoon. This preparation should be made fresh before each dose.

Paediatric dosing requires particularly careful monitoring, as children may have different pharmacokinetic profiles and sensitivities. Regular assessment of growth parameters, liver function, and serum cholestanol levels is essential. Dose adjustments should be made gradually, with intervals of at least 1 month between changes to allow for steady-state assessment.

Elderly

No specific dose adjustment is required for elderly patients based on age alone. However, given the higher likelihood of hepatic or renal impairment in this population, more frequent monitoring of liver function and clinical status is advisable. The same target of cholestanol normalisation applies, and dose titration should follow the same principles as in younger adults.

Missed Dose

If a dose is missed, it should be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Do not take a double dose to make up for a missed one. Occasional missed doses are unlikely to have significant clinical consequences given the chronic nature of CTX treatment, but consistent adherence is important for maintaining stable cholestanol levels.

Overdose

Overdose with chenodeoxycholic acid is likely to manifest primarily as diarrhoea, which is the dose-limiting adverse effect. In case of significant overdose, treatment should be symptomatic and supportive. Diarrhoea may be managed with fluid and electrolyte replacement. Cholestyramine may be used to bind excess bile acids in the intestine if necessary, though this would be a temporary measure. No specific antidote exists. Liver function should be monitored following any suspected overdose. In clinical practice, overdose events with Chenodeoxycholic acid Leadiant have not been specifically reported, likely reflecting the small patient population and specialist-supervised treatment setting.

What Are the Side Effects of Chenodeoxycholic Acid Leadiant?

The most common side effect of Chenodeoxycholic acid Leadiant is diarrhoea, which is dose-related and can usually be managed by temporary dose reduction. Other reported side effects include abdominal pain, elevated liver enzymes, and nausea. Serious side effects are uncommon when the medicine is used at recommended doses under specialist supervision.

The safety profile of chenodeoxycholic acid in CTX patients differs from its historical use in gallstone dissolution, where higher doses were employed in a different patient population. In the CTX setting, CDCA replaces a deficient endogenous substance, and the doses used are generally lower relative to the historical gallstone indications. Nevertheless, adverse effects can occur and should be monitored.

It is important to recognise that the available safety data for Chenodeoxycholic acid Leadiant in CTX is based on a limited number of patients, given the ultra-rare nature of the disease. Frequency categories below are estimated based on published case series, post-marketing data, and the EMA assessment report.

Patients should be aware that the distinction between the effects of the underlying disease (CTX) and adverse drug effects can sometimes be challenging, particularly regarding gastrointestinal symptoms, as chronic diarrhoea is also a feature of untreated CTX itself. Your specialist will help differentiate between disease-related and medication-related symptoms through biochemical monitoring and clinical assessment.

If you experience any side effects not listed here, or if any of the side effects become serious, you should report them to your physician. In the European Union, patients and healthcare professionals can also report suspected adverse reactions through the national pharmacovigilance systems.

How Should You Store Chenodeoxycholic Acid Leadiant?

Store Chenodeoxycholic acid Leadiant capsules below 30°C in the original packaging to protect from moisture. Keep out of the reach and sight of children. Do not use after the expiry date printed on the carton and blister.

Proper storage of Chenodeoxycholic acid Leadiant is important to maintain the stability and effectiveness of the medicine. The capsules should be stored at a temperature not exceeding 30°C. They should be kept in the original blister packaging to protect them from moisture, as bile acids can be hygroscopic (they absorb moisture from the air).

Do not remove the capsules from the blister packaging until you are ready to take them. If you notice any changes in the appearance of the capsules, such as discolouration, softening, or an unusual odour, do not take them and consult your pharmacist. As with all medicines, keep Chenodeoxycholic acid Leadiant out of the reach and sight of children.

Do not use the medicine after the expiry date stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment, which is particularly important for pharmaceutical products that may affect aquatic ecosystems.

If you are travelling, ensure the capsules are stored within the recommended temperature range. In hot climates, consider using an insulated medication bag. For long-distance travel, carry an adequate supply in your hand luggage along with a letter from your prescribing physician confirming the medical necessity of the medication.

What Does Chenodeoxycholic Acid Leadiant Contain?

Each hard capsule contains 250 mg of chenodeoxycholic acid as the active ingredient. The excipients include maize starch, magnesium stearate, colloidal anhydrous silica, and the capsule shell components gelatin and titanium dioxide.

Understanding the full composition of your medicine is important, particularly if you have known allergies or intolerances to any pharmaceutical excipients. The complete composition of Chenodeoxycholic acid Leadiant 250 mg hard capsules is as follows:

Active ingredient

• Chenodeoxycholic acid: 250 mg per capsule. Chenodeoxycholic acid (CDCA, also known as 3α,7α-dihydroxy-5β-cholan-24-oic acid) is a naturally occurring primary bile acid synthesised in the liver from cholesterol. It has the molecular formula C₂₄H₄₀O₄ and a molecular weight of 392.57 g/mol.

Excipients (inactive ingredients)

• Maize starch: Used as a filler and disintegrant to facilitate the breakdown of the capsule contents in the gastrointestinal tract
• Magnesium stearate: A lubricant that prevents the capsule contents from sticking to manufacturing equipment
• Colloidal anhydrous silica: A flow agent that ensures uniform distribution of the active ingredient within the capsule
• Capsule shell: Composed of gelatin and titanium dioxide (E171). The capsule shell is opaque white. Patients who avoid gelatin (for dietary or religious reasons) should discuss this with their physician

Chenodeoxycholic acid Leadiant does not contain lactose, gluten, sucrose, or preservatives. This information is relevant for patients with specific dietary restrictions or intolerances. The capsules are not suitable for patients with a known allergy to any of the listed excipients.

Frequently Asked Questions